06.08.2010 • NewsLanxessQ2 2010

Lanxess Credits 'Strategic Positioning' for Strong Q2

Lanxess has reported significantly better-than-expected results in the second quarter of 2010, which the company says is due to its strategic positioning in the emerging markets. As a result, the specialty chemicals company has raised its earnings forecast for the business year 2010. It now expects Ebitda pre exceptionals of roughly €800 million for the full year after previously forecasting €650-700 million in May 2010.

Lanxess more than doubled Ebitda pre exceptionals year-on-year to €269 million in the second quarter. Earnings were primarily driven by ongoing strong demand for synthetic rubber in Asia and notably Latin America. Ebitda margin pre exceptionals - another key performance indicator - rose to 14.7% from 9.0% a year ago. The average capacity utilization rate of the company's plants stood at more than 85% in the second quarter.
Lanxess said its top 10 sales products in the second quarter were from the company's synthetic rubber and high-tech plastic business units, which mainly serve the tire and automotive industries.

Sales increased 48% year-on-year to €1.83 billion due to higher volumes in key customer industries and positive currency effects in the form of a weaker euro against the dollar and Brazilian real. Higher raw material costs were fully passed on to customers through product price increases. The company posted a net profit of €131 million in the second quarter in comparison to €17 million a year earlier.

Net debt at the end of the second quarter 2010 rose to €955 million from €794 million from the end of 2009 due to dividend payments and an increase in net working capital. This increase was in line with stronger business activity in general. Operating cash flow before changes in working capital rose to €203 million from €71 million a year earlier.

Company

Logo:

LANXESS Deutschland GmbH

Kennedyplatz 1
50569 Köln
Germany

Company contact







Innovation Pitch

The Start-up Platform for Chemistry & Life Sciences

The Start-up Platform for Chemistry & Life Sciences

The tasks range from employee protection, site security and crisis management to IT, OT and production security.

Interview

Innovation at the Intersection of AI
Digital Potential in Key Business Areas

Innovation at the Intersection of AI

Stefan Guertzgen spoke with John Banovetz, Chief Technology Officer at 3M, about the role of digital transformation in achieving the company's objectives.

most read

Photo
19.03.2025 • NewsInnovation

Data-Driven Enzyme Immobilization

Inseit, based in Bern, develops biocatalysts for industrial setups using enzyme immobilization and biocomputation. Addressing biotech and sustainability challenges, Inseit was selected for Venture Leaders Biotech and won two Nucleate accelerator prizes.

Photo
29.10.2024 • News

GSK to Invest $800 Million in US Manufacturing Facility

British pharma company GlaxoSmithKline (GSK) plans to invest up to $800 million to expand drug substance and drug product manufacturing capabilities at the company’s US site in Marietta, Pennsylvania. The investment, which GSK said is its largest ever in US manufacturing, is expected to create more than 200 new jobs.